CONMED (CNMD) is back on investors’ radar as the medical technology company prepares to report quarterly results this Wednesday after the market close, with the market expecting a 1.5% year on year revenue decline.
See our latest analysis for CONMED.
CONMED's recent momentum has picked up, with a 30 day share price return of 23.09% and a 90 day move of 23.05%. However, the 1 year total shareholder return is down 11.68%, so shorter term optimism contrasts with weaker longer term performance.
If you are looking beyond CONMED ahead of earnings season, this could be a useful moment to scan for other medical technology opportunities via our healthcare focused 40 healthcare AI stocks
After CONMED’s sharp rebound yet still weak multi year shareholder returns, the key question is whether this latest move is simply a catch up or if the market has already priced in most of the easy upside ahead of earnings.
Most Popular Narrative: 11.7% Overvalued
CONMED's most followed narrative sets a fair value of $39.60, which sits below the latest close at $44.25, so the market is currently pricing in a premium to that view.
The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is poised to support durable procedure volume growth and increase recurring revenue, driving sustained top-line growth.
Read the complete narrative. Read the complete narrative.
Want to see how this fair value is built? The narrative leans heavily on faster earnings growth, wider margins, and a lower future earnings multiple than many peers. The exact mix of those three inputs is what really moves the valuation.
The model behind this narrative uses a 9.09% discount rate, pairs modest revenue growth with much stronger profit growth, and assumes rising profit margins over time. It then applies a future P/E that is well below the current industry level to translate those earnings into the $39.60 fair value.
Result: Fair Value of $39.60 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, for CONMED this narrative can be challenged if supply chain issues persist or if hospital capital spending and elective procedures weaken more than analysts expect.
Find out about the key risks to this CONMED narrative.
Another View on CONMED's Valuation
The narrative fair value of $39.60 suggests CONMED is 11.7% overvalued, yet our DCF model points in the opposite direction. On this view, CONMED at $44.25 trades about 61% below an estimated future cash flow value of $114.57, which implies a very different risk reward profile.
Our DCF model relies on long term cash flow assumptions and discount rates rather than market multiples, so it often reacts more slowly to sentiment shifts. The question for you is which story feels more realistic for CONMED: a market that is already ahead of itself, or one that is still pricing in a wide margin of safety.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment on CONMED clearly mixed, this is a good moment to look at the data yourself, weigh the trade offs, and see how the 3 key rewards and 3 important warning signs align with your own view.
Looking for more ideas beyond CONMED?
If you want a broader view alongside CONMED, now is the time to widen your watchlist with fresh stock ideas sourced from focused Simply Wall Street screeners.
- Target potential value opportunities by scanning companies that appear mispriced based on strong fundamentals through the 49 high quality undervalued stocks.
- Strengthen your defensive side by reviewing companies with robust finances using the solid balance sheet and fundamentals stocks screener (48 results).
- Spot earlier stage prospects with healthier metrics than typical micro caps by checking the 20 elite penny stocks with strong financials.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com